157 results
8-K
EX-99.1
SEEL
Seelos Therapeutics Inc
19 Mar 24
Other Events
4:05pm
RELYVRIO® Free (ERF)1 data set (n=130), including:
a 22% improvement in slope of change in ALSFRS-R assessment adjusted for mortality, with an 89
DEFA14A
SEEL
Seelos Therapeutics Inc
22 Dec 23
Additional proxy soliciting materials
8:10am
) biomarker and Modified Scale for Assessment and Rating of Ataxia (m-SARA) scores appear to be decreasing over the 6-month time period, which is not expected
424B3
napff908tep6z 1c4xtk
29 Sep 23
Prospectus supplement
4:56pm
424B5
9ldyuxg
25 Sep 23
Prospectus supplement for primary offering
6:02am
8-K
EX-99.1
udcft bnob
20 Sep 23
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
7:00am
8-K
EX-99.2
1nz0 updifk49pqr
20 Sep 23
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
7:00am
8-K
EX-1.1
j1klidswh
12 May 22
Entry into a Material Definitive Agreement
8:31am
8-K
EX-10.1
9lc1xera99bim0m81okb
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-4.1
0lqwwet 23y
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-1.1
lu0a6 8xx7
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
424B5
x5dgejf6zvbfuvsvr6h
21 May 21
Prospectus supplement for primary offering
12:00am